Loading
Belumosudil is a pill for chronic graft-versus-host disease, the long-term immune complication of donor stem-cell transplants used to cure blood cancers.
Belumosudil is an oral selective inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2). By rebalancing Th17 and regulatory T-cell responses and reducing fibrotic signalling, it addresses both the inflammatory and the sclerotic components of chronic graft-versus-host disease, the long-term immune complication of donor stem-cell transplants used to cure leukaemias and MDS. In ROCKstar (2021) the overall response rate was 74% in patients with cGVHD after at least two prior lines, including responses in fibrotic organ involvement. It was approved in the US in 2021 for patients aged 12 and over, alongside ruxolitinib (REACH3) and ibrutinib, and axatilimab (anti-CSF1R) followed in 2024. Sequencing among them is unsettled. Belumosudil is part of the transplant survivorship toolkit: a pill that helps donor immune attack on the patient's own tissues without broad immunosuppression.
Selective inhibition of Rho-associated coiled-coil kinase 2 rebalances Th17/Treg responses and reduces fibrosis in chronic graft-versus-host disease.
1.Belumosudil slips into a pocket on its target.
Oral, self-administered, so it is a Part D drug: covered through a stand-alone Part D plan or Medicare Advantage drug benefit, usually on the specialty tier with 25 to 33% coinsurance until the annual cap ($2,000 in 2025, $2,100 in 2026). Rezurock (chronic GVHD) is a Part D specialty drug.
Covered for FDA-labelled and NCCN-listed uses, but almost always behind prior authorisation confirming diagnosis, biomarker and line of therapy; dispensed through a specialty pharmacy. Plans require failure of at least two prior lines of systemic therapy for chronic GVHD, per the label.
Part D out-of-pocket capped at $2,000 (2025) / $2,100 (2026). Medicare patients cannot use manufacturer co-pay cards; charity funds (PAN, HealthWell, CancerCare) and the Extra Help subsidy are the routes.
Sources: Medicare.gov: Drug coverage (Part D) · Medicare.gov: Costs for Medicare drug coverage (annual out-of-pocket cap). Not medical or financial advice; verify with your plan.
Sources: NICE TA949. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
Compare all products across the US, EU, UK, Japan, China and Australia →
| Region | Year | Indication |
|---|---|---|
| US | 2021 | Chronic GVHD after failure of ≥2 lines of systemic therapy (age ≥12) |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Belumosudil" OR ABSTRACT:"Belumosudil" OR TITLE:"Rezurock" OR ABSTRACT:"Rezurock") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Belumosudil, not a curated reading list.
Shares Allogeneic stem cell transplantation, Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tag supportive.
Shares Sanofi, Acute lymphoblastic leukaemia, Acute myeloid leukaemia and the tag supportive.
Shares Allogeneic stem cell transplantation, Myelodysplastic syndromes / neoplasms (MDS), Acute lymphoblastic leukaemia, Acute myeloid leukaemia and the tag supportive.
Shares Allogeneic stem cell transplantation and the tag supportive.
Shares Sanofi and the tag supportive.
Shares Sanofi and the tag supportive.
Shares Acute lymphoblastic leukaemia and the tag supportive.
Shares Myelodysplastic syndromes / neoplasms (MDS) and the tag supportive.